Astute Medical Newswire

Astute Medical Newswire

Comprehensive Real-Time News Feed for Astute Medical.

Results 1 - 10 of 10 in Astute Medical

  1. Ortho Clinical Diagnostics VITROS(r) NephroCheck(r) Test for...Read the original story w/Photo

    Friday Jul 28 | Newswise

    ... It provides both clinical and economic value." The VITROS NephroCheck was developed under license from Astute Medical. The NephroCheck test was discovered and validated as an AKI risk assessment tool for the development of moderate to severe AKI in ...

    Comment?

  2. Ortho Clinical Diagnostics VITROS NephroCheck Test For Prediction Of...Read the original story

    Jun 6, 2017 | BioSpace

    ... It provides both clinical and economic value." The VITROS NephroCheck was developed under license from Astute Medical. The NephroCheck test was discovered and validated as an AKI risk assessment tool for the development of moderate to severe AKI in ...

    Comment?

  3. Ortho Clinical Diagnostics VITROS NephroCheck Test For Prediction Of...Read the original story

    Jun 5, 2017 | BioSpace

    ... It provides both clinical and economic value." The VITROS NephroCheck was developed under license from Astute Medical. The NephroCheckA test was discovered and validated as an AKI risk assessment tool for the development of moderate to severe AKI in ...

    Comment?

  4. Ortho Clinical Diagnostics VITROS(R) NephroCheck(R) Test for...Read the original story

    Jun 5, 2017 | GlobeNewswire

    ... It provides both clinical and economic value." The VITROS NephroCheck was developed under license from Astute Medical. The NephroCheckA test was discovered and validated as an AKI risk assessment tool for the development of moderate to severe AKI in ...

    Comment?

  5. Astute Medical Previews Scientific Presentations At UpcomingRead the original story

    Mar 15, 2017 | BioSpace

    The presentations relate to study of the biomarkers TIMP-2 and IGFBP-7, which were identified1 and validated2 as biomarkers of AKI risk in clinical studies leading to the commercialization of Astute Medical's NephroCheck Test. Title: The Role of Biomarkers Speaker: Ivan Gocze, M.D. Date: Wednesday, March 22 Time: 5:30-5:45 p.m. "We are pleased to see yet another major conference where respected thought leaders from around the world will be presenting the results of their investigations highlighting the practical clinical utility of the NephroCheck Test to gauge the risk of acute kidney injury before damage occurs," said , Astute Medical chief scientific officer.

    Comment?

  6. Astute Medical Release: Biomarkers Accurately Predict Acute Kidney...Read the original story

    Mar 14, 2017 | BioSpace

    /PRNewswire/ -- Astute Medical, Inc., developer of biomarkers for better healthcare, today said that newly published findings show the NephroCheck Test could help clinicians identify risk of acute kidney injury (AKI) in patients with a sudden ...

    Comment?

  7. Astute MedicalPreviews Scientific Presentations At Upcoming International Nephrology ConferenceRead the original story

    Mar 5, 2017 | BioSpace

    The presentations relate to study of the biomarkers TIMP-2 and IGFBP-7, which were identified1 and validated2 as biomarkers of AKI risk in clinical studies leading to the commercialization of Astute Medical's NephroCheck Test. Title: Cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] for risk stratification of acute kidney injury in patients with sepsis Authors: Marco Fiorentino Ph.D., C Keener, A Smith, " We are pleased to see more investigations into the practical clinical utility of the NephroCheck Test biomarkers as a means of gauging the risk for AKI before damage occurs," said , Astute Medical chief scientific officer.

    Comment?

  8. Astute Medical Says First In Texas To Start Biomarker-Based AKI...Read the original story

    Jan 4, 2017 | BioSpace

    AKI is a stealthy, unpredictable and dangerous complication known to strike up to half of the 5.7 million people admitted to intensive care units in Clinicians at Methodist Dallas are using Astute Medical's NephroCheck Test to quickly identify patients at risk of developing moderate to severe AKI so that intervention can occur early enough to reduce the threat of irreparable kidney damage. If left undetected, AKI can quickly lead to permanent kidney damage that can result in long-term complications and death.2 , M.D., F.A.C.P, program director, nephrology fellowship program at Methodist Dallas.

    Comment?

  9. Bio-Techne And Astute Medical Form Strategic PartnershipRead the original story

    Dec 14, 2016 | BioSpace

    Certain existing Astute Medical investors also participated in the financing, which totaled . This transaction has been structured to allow Bio-Techne to build a strategic foundation in diagnostics, with an option to further expand the relationship.

    Comment?

  10. BRIEF-Bio-techne and Astute Medical form strategic partnershipRead the original story w/Photo

    Dec 14, 2016 | Reuters

    CHICAGO, Dec 14 The U.S. Department of Agriculture proposed rules on Wednesday it said will help protect chicken producers from mistreatment by the small group of meat companies that control most of the country's production.

    Comment?